Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment

In the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy was non-inferior to whole-breast external beam radiotherapy, for local recurrence. In the long-term, no difference was found in any breast cancer outcome, whereas there were fewer deat...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaidya, Jayant S., Bulsara, Max, Baum, Michael, Tobias, Jeffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851812/
https://www.ncbi.nlm.nih.gov/pubmed/33531693
http://dx.doi.org/10.1038/s41416-020-01233-5
Descripción
Sumario:In the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy was non-inferior to whole-breast external beam radiotherapy, for local recurrence. In the long-term, no difference was found in any breast cancer outcome, whereas there were fewer deaths from non-breast-cancer causes. TARGIT-IORT should be included in pre-operative consultations with eligible patients.

Ejemplares similares